Orchard Therapeutics (ORTX) Scheduled to Post Quarterly Earnings on Thursday

Orchard Therapeutics (NASDAQ:ORTX – Get Rating) will be releasing its earnings data before the market opens on Thursday, May 12th. Analysts expect Orchard Therapeutics to post earnings of ($0.25) per share for the quarter.

Orchard Therapeutics (NASDAQ:ORTX – Get Rating) last posted its quarterly earnings results on Wednesday, March 30th. The company reported ($0.29) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.29). The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.65 million. During the same quarter in the prior year, the business earned ($0.34) earnings per share. On average, analysts expect Orchard Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ ORTX traded down $0.02 during midday trading on Friday, hitting $0.49. The company had a trading volume of 6,900 shares, compared to its average volume of 384,984. The company has a quick ratio of 6.43, a current ratio of 6.43 and a debt-to-equity ratio of 0.15. The stock has a market cap of $62.27 million, a price-to-earnings ratio of -0.43 and a beta of 1.20. The firm has a fifty day simple moving average of $0.72 and a two-hundred day simple moving average of $1.14. Orchard Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $5.99.

Several large investors have recently added to or reduced their stakes in ORTX. Morgan Stanley lifted its holdings in Orchard Therapeutics by 368.7% during the 2nd quarter. Morgan Stanley now owns 85,431 shares of the company’s stock valued at $375,000 after purchasing an additional 67,205 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Orchard Therapeutics during the 3rd quarter valued at about $40,000. Millennium Management LLC lifted its holdings in Orchard Therapeutics by 1,740.2% during the 3rd quarter. Millennium Management LLC now owns 411,713 shares of the company’s stock valued at $947,000 after purchasing an additional 389,340 shares during the last quarter. Jane Street Group LLC bought a new position in Orchard Therapeutics during the 3rd quarter valued at about $29,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Orchard Therapeutics by 134.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 73,332 shares of the company’s stock valued at $97,000 after purchasing an additional 41,997 shares during the last quarter. 56.47% of the stock is owned by institutional investors.

ORTX has been the topic of several research analyst reports. Stifel Nicolaus decreased their price target on shares of Orchard Therapeutics from $12.00 to $5.00 in a research report on Thursday, March 31st. Zacks Investment Research upgraded shares of Orchard Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 2nd. Cowen downgraded shares of Orchard Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, March 31st. Finally, Sumitomo Mitsui Financial Group reaffirmed a “neutral” rating on shares of Orchard Therapeutics in a report on Friday, April 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Orchard Therapeutics currently has a consensus rating of “Hold” and an average price target of $10.25.

About Orchard Therapeutics (Get Rating)

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.

Featured Articles